US 12,070,447 B2
Parenteral liquid preparation comprising carbamate compound
Myoung Ki Baek, Gyeonggi-do (KR); Ji Hye Lee, Gyeonggi-do (KR); and So Young Choi, Gyeonggi-do (KR)
Assigned to SK BIOPHARMACEUTICALS CO., LTD., Gyeonggi-do (KR)
Appl. No. 16/468,756
Filed by SK BIOPHARMACEUTICALS CO., LTD., Gyeonggi-do (KR)
PCT Filed Dec. 14, 2017, PCT No. PCT/KR2017/014727
§ 371(c)(1), (2) Date Jun. 12, 2019,
PCT Pub. No. WO2018/111000, PCT Pub. Date Jun. 21, 2018.
Claims priority of application No. 10-2016-0170389 (KR), filed on Dec. 14, 2016.
Prior Publication US 2019/0314336 A1, Oct. 17, 2019
Int. Cl. A61K 31/41 (2006.01); A61K 9/00 (2006.01); A61K 9/19 (2006.01); A61K 47/40 (2006.01)
CPC A61K 31/41 (2013.01) [A61K 9/0019 (2013.01); A61K 47/40 (2013.01)] 5 Claims
OG exemplary drawing
 
1. A parenteral liquid formulation comprising as a sole active ingredient a carbamate compound which is carbamic acid (R)-1-(2-chlorophenyl)-2-tetrazol-2-yl-ethyl ester of the following Formula 2, or a pharmaceutically acceptable salt, solvate or hydrate of the compound of Formula 2; and a cyclodextrin derivative:

OG Complex Work Unit Chemistry
wherein the cyclodextrin derivative is 2-hydroxypropyl-β-cyclodextrin or sulfobutyl ether-β-cyclodextrin, and
wherein a weight ratio of the active ingredient to the cyclodextrin derivative is 1:5 to 1:40; and
wherein the carbamate compound of Formula 2 and the cyclodextrin form an inclusion complex.